Amy Wakeham - ResMed VP Communications

RME Stock  EUR 222.20  1.40  0.63%   

Insider

Amy Wakeham is VP Communications of ResMed Inc
Phone858 836 5000
Webhttps://www.resmed.com

ResMed Management Efficiency

The company has return on total asset (ROA) of 0.1155 % which means that it generated a profit of $0.1155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2352 %, meaning that it generated $0.2352 on every $100 dollars invested by stockholders. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities.
ResMed Inc has accumulated 765.33 M in total debt with debt to equity ratio (D/E) of 61.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ResMed Inc has a current ratio of 2.02, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist ResMed until it has trouble settling it off, either with new capital or with free cash flow. So, ResMed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ResMed Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ResMed to invest in growth at high rates of return. When we think about ResMed's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

John MackaySartorius Aktiengesellschaft
61
Vered KeisarResmed Inc DRC
N/A
Amelie ButonSartorius Stedim Biotech
32
Manohar KuppusamiSartorius Aktiengesellschaft
N/A
Rene FaberSartorius Aktiengesellschaft
48
Paul SaillantEssilorLuxottica Socit anonyme
64
Jamie SamathIntuitive Surgical
52
David RosaIntuitive Surgical
55
MD FACSIntuitive Surgical
66
Robert DeSantisIntuitive Surgical
57
Mei WangSartorius Aktiengesellschaft
N/A
Rashid MaqboolSartorius Aktiengesellschaft
N/A
Patricia SpannagelSartorius Aktiengesellschaft
N/A
Heiko ImhlSartorius Stedim Biotech
N/A
Francesco MilleriEssilorLuxottica Socit anonyme
64
Brett SandercockResmed Inc DRC
56
Philip KimIntuitive Surgical
N/A
AM AMResmed Inc DRC
80
Pascale BoisselSartorius Stedim Biotech
N/A
Rainer LehmannSartorius Aktiengesellschaft
48
Stefano GrassiEssilorLuxottica Socit anonyme
50
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. RESMED INC is traded on Frankfurt Stock Exchange in Germany. ResMed Inc (RME) is traded on Frankfurt Exchange in Germany and employs 8,160 people.

Management Performance

ResMed Inc Leadership Team

Elected by the shareholders, the ResMed's board of directors comprises two types of representatives: ResMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ResMed. The board's role is to monitor ResMed's management team and ensure that shareholders' interests are well served. ResMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ResMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Amy Wakeham, VP Communications
Brett Sandercock, Chief Officer
BE MBA, CEO Director
Robert Douglas, Pres COO
Vered Keisar, Chief Officer
AM AM, Founder Chairman
David Pendarvis, Global Officer
Kaushik Ghoshal, Pres Bus
Constance Bienfait, Director Relations
Urvashi Tyagi, Chief Officer

ResMed Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ResMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in ResMed Stock

When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.